Amgen and Gilead deliver lacklustre early clinical results with AMG 355 and denikitug respectively.
ApexOnco Front Page
Recent articles
Lilly makes its second in vivo Car-T acquisition, buying the privately held Kelonia for $3.25bn.
After setbacks, cema-cel might have a path to approval in lymphoma.
The group impresses in ovarian and endometrial cancers.
Optimum-02 virtually replicates phase 1, and a filing will follow.
The oncolytic virus vuso-vec is slapped with its second CRL.
After opting in last year, Gilead picks up Kymera's KT-200.
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
